Adding Immuron (IMRN) $2.57 to Superbug Watchlist.
CLICK FOR LIVE QUOTE
SUPER BUG STOCK REVIEW
Prevent Montezuma's Revenge BEFORE it starts! Immuron's direct to consumer product Travelan® is a huge hit with international...
Adding Todos Medical (TODMF) $0.03 to SuperBug Stock Review Watchlist.
Wall Street's War Against SuperBugs.
LIVE QUOTE
SuperBug Stock Review? Yep, you knew we couldn't resist with all of the CoronaVirus news hitting the tape. Since...
VirnetX (VHC) Scores $440 Million and Citius Pharma (CTXR) Sees Market Expand to Over...
Internet Stock Review
Blast from the past scores big!
We added VirnetX (VHC) to the Watch List (Patent Stock Review, since shuttered) back in 2010....
Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.
Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.
Citius Pharma (CTXR) Inches Closer to the Next Phase III Data Announcement.
Citius Pharma Presenting at...
Video: How Superbugs Get Started.
A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening right now...
Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019 - Data Analysis Back, Results Positive.February...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next...
Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.
STREET INSIDER
H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals (NASDAQ: CTXR) to $4.00 (from $1.65) while maintaining a Buy rating.
The analyst commented,...
VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).
Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...
Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...
Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially improve the...